Company Overview and News
KUALA LUMPUR (Oct 16): The FBM KLCI pared some of its gains at midday break today, as sellers outpaced buyers at the local bourse, against the backdrop of modest gains at regional markets.
HLFBF 7113 BATS TPGVF 4162 5037 2089 9334 5199 3867 2836 HIPEF UPBMF 1082 5220 5681 7765 7066 0131 7123 TGLVY 5139 4588 0900 5819
KUALA LUMPUR (Oct 16): The FBM KLCI reversed its earlier losses and climbed at mid-morning, tracking the modest rise at the regional markets.
UPBMF 5220 7113 5681 TPGVF BATS 4162 2291 2089 5014 7066 0131 6033 7123 5199 TGLVY 4588 PNADF 0026 MYPRY HIPEF PNAGF GEBHF
KUALA LUMPUR, Oct 5 ― Bursa Malaysia ended in negative territory today in line with its Asian peers on continued selling in selected heavyweights in the telecommunications, utilities, consumer products and services, and finance sectors.
PNADF PBLOF 7036 5681 1295 BSMAF 7066 PNAGF 6033 1818
KUALA LUMPUR: Yong Tai Bhd’s focus for the financial year ending June 30, 2019 (FY19) will be on Encore Melaka, as well as clearing the remaining inventories for its property segment, which stood at about RM400 million.
KUALA LUMPUR: Yong Tai Bhd is optimistic that its Impression Series — Encore Melaka, a live performance highlighting the city’s rich history and cultural heritage will successfully deliver on its ticket sales target of 85,000 a month, over the next six to nine months.
Yong Tai Bhd (Aug 14, RM1.12) Outperform with an unchanged target price of RM2.25: Management of Yong Tai Bhd met up with the investment fraternity to provide current updates on the Encore Melaka theatre while also fielding questions about various other issues, one of which included the recent announcement of the early conversion of preference shares and subsequent share price weakness. While certain operational challenges were acknowledged, the long-term intrinsic value of the group’s undertakings remains unchanged.
KUALA LUMPUR: Blue chips started Tuesday on a firm note, outperforming the steady key Asian markets, but analysts expect some pullback following the recent overbought conditions.
TGLVY PNADF 7113 5681 TPGVF BSMAF 7066 PNAGF 6033 1818
IT is set to be a big year for Yong Tai Bhd as the curtain goes up on its live performance, Encore Melaka. If everything goes to plan, the group could see a tenfold jump in profit with revenue potentially growing as much as six to seven times in the financial year ending June 30, 2019 (FY2019).
AAPL 0707 7066
THE property market is still soft with most developers experiencing slow sales. Most property developers, it seems, are taking a cautiously optimistic view of the market in the near term. According to some of the developers participating in EdgeProp.my’s Malaysia Virtual Property Expo (VPEX) 2018, the days ahead will remain challenging but they are feeling a tad more optimistic of the future than before.
5789 5148 5236 7066
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...